These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 37396067)
21. [Analysis of related factors of carbapenem resistant Klebsiella pneumoniae infection in patients with artificial airway]. Bian W; Chen W; Gu X; Wang S; Liu Y; Zhao G; Qin Y Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Nov; 32(11):1324-1330. PubMed ID: 33463491 [TBL] [Abstract][Full Text] [Related]
22. Polymyxin B/Tigecycline Combination vs. Polymyxin B or Tigecycline Alone for the Treatment of Hospital-Acquired Pneumonia Caused by Carbapenem-Resistant Chang K; Wang H; Zhao J; Yang X; Wu B; Sun W; Huang M; Cheng Z; Chen H; Song Y; Chen P; Chen X; Gan X; Ma W; Xing L; Wang Y; Gu X; Zou X; Cao B Front Med (Lausanne); 2022; 9():772372. PubMed ID: 35755062 [TBL] [Abstract][Full Text] [Related]
23. A Retrospective Analysis of Risk Factors and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in Nontransplant Patients. Xiao T; Zhu Y; Zhang S; Wang Y; Shen P; Zhou Y; Yu X; Xiao Y J Infect Dis; 2020 Mar; 221(Suppl 2):S174-S183. PubMed ID: 32176799 [TBL] [Abstract][Full Text] [Related]
24. Risk factors for carbapenem-resistant Dai G; Xu Y; Kong H; Xie W; Wang H Am J Transl Res; 2021; 13(6):7276-7281. PubMed ID: 34306493 [TBL] [Abstract][Full Text] [Related]
25. Polymyxin B-Based Regimens for Patients Infected with Carbapenem-Resistant Gram-Negative Bacteria: Clinical and Microbiological Efficacy, Mortality, and Safety. Qu J; Qi TT; Qu Q; Long WM; Chen Y; Luo Y; Wang Y Infect Drug Resist; 2022; 15():1205-1218. PubMed ID: 35345474 [TBL] [Abstract][Full Text] [Related]
27. An Outbreak of Carbapenem-Resistant Zeng L; Yang C; Zhang J; Hu K; Zou J; Li J; Wang J; Huang W; Yin L; Zhang X Front Cell Infect Microbiol; 2021; 11():656070. PubMed ID: 34150672 [TBL] [Abstract][Full Text] [Related]
28. Carbapenem-resistant hypermucoviscous Wang Q; Chen M; Ou Q; Zheng L; Chen X; Mao G; Fang J; Jin D; Tang X Front Cell Infect Microbiol; 2022; 12():1083009. PubMed ID: 36619764 [TBL] [Abstract][Full Text] [Related]
29. Analysis of the Drug Resistance of Carbapenem-Resistant Gao L; Lv Y; Li Y Microb Drug Resist; 2020 Aug; 26(8):944-950. PubMed ID: 32043901 [No Abstract] [Full Text] [Related]
30. Bloodstream Infections due to Carbapenem-Resistant Shen L; Lian C; Zhu B; Yao Y; Yang Q; Zhou J; Zhou H Microb Drug Resist; 2021 Feb; 27(2):227-233. PubMed ID: 32584202 [TBL] [Abstract][Full Text] [Related]
31. Healthcare-associated carbapenem-resistant Klebsiella pneumoniae bloodstream infections: Risk factors, mortality, and antimicrobial susceptibility, 2017-2019. Hsu JY; Chuang YC; Wang JT; Chen YC; Hsieh SM J Formos Med Assoc; 2021 Nov; 120(11):1994-2002. PubMed ID: 33962811 [TBL] [Abstract][Full Text] [Related]
32. Relationship between antibiotic exposure and carbapenem-resistant Klebsiella pneumoniae infection within four types of control patients: A systematic review and meta-analysis. Zhu L; Liang L; Hui J; Lu J; Yang R; He Q; Tian N; Bai T; Li X J Glob Antimicrob Resist; 2023 Jun; 33():137-151. PubMed ID: 36906174 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of ceftazidime-avibactam compared to other antimicrobials for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae strains, a systematic review and meta-analysis. Karampatakis T; Tsergouli K; Lowrie K Microb Pathog; 2023 Jun; 179():106090. PubMed ID: 37004964 [TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study. Zhang X; Qi S; Duan X; Han B; Zhang S; Liu S; Wang H; Zhang H; Sun T J Transl Med; 2021 Oct; 19(1):431. PubMed ID: 34656132 [TBL] [Abstract][Full Text] [Related]
35. Molecular Epidemiology and Risk Factors of Carbapenem-Resistant Klebsiella Pneumoniae Bloodstream Infections in Wuhan, China. Liu C; Liu L; Jin MM; Hu YB; Cai X; Wan L; Zhang HY; Li RY; Wu XJ Curr Med Sci; 2022 Feb; 42(1):68-76. PubMed ID: 34985611 [TBL] [Abstract][Full Text] [Related]
36. Risk Factors and Molecular Mechanism of Polymyxin B Resistance in Carbapenem-Resistant Xu X; Zhu R; Lian S; Zhang H; Chen X; Fan L; Chen P; Cao Y Infect Drug Resist; 2022; 15():7485-7494. PubMed ID: 36544993 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety Factors Related to Plasma Concentration-Optimized Polymyxin B Therapy in Treating Carbapenem-Resistant Gram-Negative Bacterial Infections in China. Li L; Huang X; Liu J; Li C; Lin Z; Ren R; Zhang Y; Ding H; Chen J; Mao Y Infect Drug Resist; 2024; 17():3057-3071. PubMed ID: 39050834 [TBL] [Abstract][Full Text] [Related]